3M Stock History and Valuation

Direct Answer

3M Company (ticker MMM, CIK 0000066740) has been listed on the New York Stock Exchange since 1950. The company completed five stock splits, all 2-for-1, between 1959 and 1999, for a cumulative factor of 32x. 3M paid consecutive dividend increases for 66 years and achieved Dividend King status, but in April 2024, following the spinoff of its healthcare business into Solventum, it reduced its quarterly dividend from $1.51 to $0.70 per share, ending that streak. 3M joined the Dow Jones Industrial Average on August 9, 1976, and remains a continuous member. At end-2024 the stock traded near $140 per share, with a market cap of approximately $77 billion and an adjusted P/E of approximately 19x.

NYSE listing history

3M Company has been listed on the New York Stock Exchange under the ticker MMM since 1950, giving it one of the longest continuous public listing histories among current Dow components. The company's CIK with the SEC is 0000066740. Over the decades following listing, 3M grew from a primarily U.S.-based industrial manufacturer into a global conglomerate operating across safety, consumer, industrial, transportation, and healthcare markets.

The stock's long listing history reflects the company's origins as Minnesota Mining and Manufacturing, founded in 1902. By the time of NYSE listing in 1950, 3M had already built a portfolio of industrial and adhesive products, including Scotch tape and masking tape, that would anchor decades of compounding returns for early shareholders.

Stock split history

3M has completed five stock splits, all of them 2-for-1, between 1959 and 1999. The cumulative split factor is 32x, meaning one share held continuously from before the 1959 split became 32 shares after the 1999 split. 3M has not split its stock since 1999.

All five splits used a 2-for-1 ratio, the most common split structure. Each split halved the nominal share price and doubled the share count, making the stock more accessible to retail investors at prices that were high relative to the market at the time. Since 1999, the share price has not reached a level that prompted management to split again, and the company has not announced any plans to do so.

Key price history

3M's share price history reflects its evolution from a steady compounding industrial to a more volatile stock beset by litigation and restructuring concerns in recent years.

The prolonged decline from the 2018 all-time high of approximately $259 to approximately $112 by late 2022 was driven by multiple converging headwinds: mounting legal exposure from Combat Arms earplugs used by military personnel, growing PFAS (per- and polyfluoroalkyl substances) environmental liability, and a series of operational misses as the company attempted to restructure its business mix. The stock's recovery in 2023 and 2024 reflected progress on settling the Combat Arms litigation and management steps to separate the healthcare segment.

Dow Jones Industrial Average membership

3M was added to the Dow Jones Industrial Average on August 9, 1976, and has been a continuous member for nearly 50 years. That tenure makes it one of the longer-serving current Dow components. The Dow is a price-weighted index, meaning higher-priced stocks carry proportionally more weight regardless of market capitalization. At its January 2018 all-time high of approximately $259 per share, MMM was one of the heaviest-weighted components in the index.

The decline from 2018 to 2022 substantially reduced 3M's Dow weight. As of end-2024 at approximately $140 per share, MMM carries a moderate weight in the 30-stock index. Changes to 3M's share price have a measurable effect on the Dow's daily point moves, which means institutional investors tracking the Dow pay close attention to MMM's price action independent of its market-cap implications.

Dividend history and the end of the Dividend King streak

3M paid consecutive annual dividend increases for 66 years, a run that qualified it as a Dividend King, a classification reserved for companies with at least 50 consecutive years of dividend growth. That streak ended in April 2024 when 3M reduced its quarterly dividend from $1.51 to $0.70 per share, following the spinoff of its healthcare business into a separately listed company called Solventum.

The dividend reduction was a direct consequence of the Solventum spinoff structure. When the healthcare business was separated, the combined dividend payout was split between the two entities, with 3M's standalone dividend reset to reflect a smaller, restructured industrial company. The $0.70 quarterly rate represents $2.80 annualized, compared to $6.04 annualized at the prior $1.51 quarterly rate. Investors who held 3M specifically for its Dividend King credentials faced a significant income reduction regardless of any share price movement.

3M's loss of Dividend King and Dividend Aristocrat status is a fundamental change in its investment classification. Many income-focused funds and indices that hold only Dividend Kings or Aristocrats were required to sell their MMM positions, which contributed to selling pressure on the stock around the time of the April 2024 spinoff.

The 2024 Solventum spinoff

On April 1, 2024, 3M completed the separation of its healthcare business segment into an independent publicly traded company called Solventum Corporation, listed on the NYSE under the ticker SOLV. 3M retained an approximate 19.9% stake in Solventum at the time of separation, with plans to divest that stake over time.

The spinoff created significant accounting complexity for investors evaluating 3M's post-separation financials. Revenue, earnings, and margins for 3M on a standalone basis after April 2024 reflect only the remaining industrial, safety, and consumer businesses, and are not directly comparable to pre-spinoff reported figures without adjustment. The dividend reduction, the index exclusion for Dividend Aristocrat and Dividend King indices, and the need to separately value the retained Solventum stake all contributed to uncertainty around MMM's fair value in the months following separation.

Valuation context

At end-2024, 3M traded at approximately $140 per share, implying a market capitalization of approximately $77 billion based on roughly 550 million diluted shares. Several valuation observations are relevant to understanding where the stock sits relative to its own history and to industrial peers.

Adjusted P/E ratio

On an adjusted earnings per share basis, 3M reported approximately $7.30 for fiscal year 2024, implying an adjusted P/E of approximately 19x at $140 per share. The GAAP P/E varies significantly from year to year because of large, one-time charges related to litigation settlements, restructuring costs, and the Solventum separation. Investors in 3M typically focus on adjusted EPS to strip out these items when assessing the ongoing earnings power of the remaining industrial portfolio.

Historical P/E discount

At approximately 19x adjusted earnings, 3M trades at a discount to its historical P/E multiple, which averaged higher during periods when it combined reliable dividend growth with healthcare exposure. The discount reflects several structural changes: the loss of Dividend King status and associated index demand, the reduced dividend, the removal of healthcare segment earnings, and lingering uncertainty about the eventual size of PFAS environmental liability. Whether this discount represents a value opportunity depends on the success of restructuring under CEO Bill Brown and whether PFAS liability estimates prove conservative or aggressive relative to eventual settlements.

Dividend yield and income characteristics

At approximately 2.0% dividend yield, 3M offers less income than it did during its Dividend King years, when yields sometimes exceeded 3% to 4% as the share price declined but the dividend continued to grow. For income investors, the 2.0% yield on a company that is no longer growing its dividend represents a materially different risk-reward profile than the prior dividend-growth investment case.

PFAS liability tail risk

PFAS environmental contamination claims represent the most significant uncertainty in any 3M valuation. The company has reached partial settlements but total PFAS liability across water systems, military bases, and other contamination sites remains incompletely quantified. Analyst estimates for ultimate PFAS liability have ranged widely. Until a more definitive resolution emerges, the PFAS tail risk acts as a ceiling on 3M's P/E multiple relative to industrial peers with cleaner liability profiles.

Frequently Asked Questions

More on 3M Company

• 3M Company (MMM) company overview

References

• 3M Company Investor Relations
• SEC EDGAR: 3M Company Form 10-K Filings (CIK 0000066740)